BIOCRYST PHARMACEUTICALS INC
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No enriched coverage for $BCRX in the last 7 days.
No SEC Form 4 filings for $BCRX in the last 30 days.
See all $BCRX insider activity →BioCryst Pharmaceuticals (BCRX) formed a Scientific Advisory Board with seven experts in rare disease research. The board will guide the company's R&D strategy and pipeline development, focusing on external innovation. BioCryst has commercialized ORLADEYO and is advancing a pipeline of rare disease therapeutics.
Anthropic’s Claude AI sold positions in Ardelyx (ARDX) and Aris Mining (ARIS), buying Syndax Pharmaceuticals (SNDX) and BioCryst (BCRX). BioCryst's Orladeyo treats hereditary angioedema, with patent protection until 2040. Despite competition concerns, Claude sees potential in BioCryst's growth and hedging strategy. The company's earnings report in early November is a key focus.
BioCryst Pharmaceuticals (BCRX) received approval in Japan for its drug ORLADEYO to treat children aged 2-12 with hereditary angioedema, expanding its global reach. The company reported Q2 revenue of $218.3M, up 34% YoY, and $98.5M in operating profit. BCRX has a forward P/E of 14.86 and positive free cash flow, supporting its growth strategy.
Recent BCRX coverage spans financial news, regulation and mergers & acquisitions.
The advisory board may improve R&D efficiency and pipeline progress, potentially supporting the stock modestly.
Claude's purchase may signal a short‑term bullish bias for BCRX ahead of its early‑November earnings.
Regulatory clearance unlocks a new revenue stream in Japan and may boost global sales.
The acquisition and upcoming licensing deals could boost revenue outlook and drive stock upside.
Profitability may boost investor confidence, but heavy reliance on Orladeyo and sizable debt pose risks to future acquisitions.
AlphAI scores every news story that mentions BCRX with an AI model for sentiment and relevance, and aggregates insider trades from BIOCRYST PHARMACEUTICALS INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
BioCryst Pharmaceuticals (BCRX) formed a Scientific Advisory Board with seven experts in rare disease research. The board will guide the company's R&D strategy and pipeline development, focusing on external innovation. BioCryst has commercialized ORLADEYO and is advancing a pipeline of rare disease therapeutics.
1 min readAnthropic’s Claude AI sold positions in Ardelyx (ARDX) and Aris Mining (ARIS), buying Syndax Pharmaceuticals (SNDX) and BioCryst (BCRX). BioCryst's Orladeyo treats hereditary angioedema, with patent protection until 2040. Despite competition concerns, Claude sees potential in BioCryst's growth and hedging strategy. The company's earnings report in early November is a key focus.
2 min readBioCryst Pharmaceuticals (BCRX) received approval in Japan for its drug ORLADEYO to treat children aged 2-12 with hereditary angioedema, expanding its global reach. The company reported Q2 revenue of $218.3M, up 34% YoY, and $98.5M in operating profit. BCRX has a forward P/E of 14.86 and positive free cash flow, supporting its growth strategy.
2 min readBioCryst acquired Astria for ~$700M, aiming for $1B rare-disease market. Focus on ORLADEYO, with 60% patient retention. Plans for navenibart and BCX17725. Expects growth in HAE market, pediatric use, and normal C1 inhibitor patients. Maintains profitability.
2 min readBioCryst Pharmaceuticals (BCRX) reported its first profit, driven by sales of Orladeyo, and plans to acquire more rare disease treatments. CEO Charlie Gayer aims to grow profits annually without external capital. Orladeyo is projected to generate up to $645M in 2026 sales. The company recently acquired Astria Therapeutics, adding navenibart to its pipeline. BioCryst has $822M in debt and relies heavily on Orladeyo for growth.
3 min readBioCryst Pharmaceuticals (BCRX) shares fell 9% on Tuesday, their worst day in over 6 months, after competitor Pharvaris (PHVS) reported positive late-stage trial results for a rare swelling disorder treatment. PHVS shares rose 7% during trading and 3% after-hours. Orladeyo, BioCryst's approved treatment, generated over $2B in revenue since 2020 and is expected to bring in $625M-$645M this year. BioCryst is also developing a second treatment, navenibart, with late-stage data expected in 2027.
2 min readRBC Capital downgraded BioCryst Pharmaceuticals (BCRX) to 'Sector Perform' and cut its price target to $11, citing competition from Pharvaris's (PHVS) strong HAE therapy data. BCRX shares fell 8%, heading for a fifth straight day of losses. Orladeyo's revenue is expected to drop to $400M-$450M due to competition, though Navenibart's Phase 3 data is awaited in 2027.
2 min readGilead (GILD) and Roivant (ROIV) received FDA approvals for Bixlenvo and LISRAYA, respectively. Johnson & Johnson (JNJ) also gained approval for IMAAVY. Biohaven (BHVN) and Eli Lilly (LLY) advanced partnerships. Spyre Therapeutics missed a clinical trial goal. Key stocks: GILD +0.52%, ROIV +2.26%, JNJ -1.57%.
3 min readBioCryst Pharmaceuticals, with a market cap under $5B, reported profitability and plans to expand through acquisitions in the rare disease space. Its FDA-approved drug Orladeyo generated over $2B in sales, with $645M forecasted for 2023. CEO Charlie Gayer aims to leverage the company's financial stability to acquire early-stage assets, targeting smaller peak sales potentials.
3 min readBioCryst Pharmaceuticals (BCRX) received Japanese approval for ORLADEYO in pediatric HAE patients aged 2 to under 12. This is the first oral prophylactic therapy for children in Japan, supported by APeX-P trial data. BCRX stock closed at $9.68, up 1.36%, and is trading at $9.72 in pre-market.
2 min read
